Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Transfers to Hemodialysis Among US Patients Initiating Renal Replacement Therapy With Peritoneal Dialysis.

McGill RL, Weiner DE, Ruthazer R, Miskulin DC, Meyer KB, Lacson E Jr.

Am J Kidney Dis. 2019 Jul 10. pii: S0272-6386(19)30801-7. doi: 10.1053/j.ajkd.2019.05.014. [Epub ahead of print]

PMID:
31301926
2.

The TiME Trial: A Fully Embedded, Cluster-Randomized, Pragmatic Trial of Hemodialysis Session Duration.

Dember LM, Lacson E Jr, Brunelli SM, Hsu JY, Cheung AK, Daugirdas JT, Greene T, Kovesdy CP, Miskulin DC, Thadhani RI, Winkelmayer WC, Ellenberg SS, Cifelli D, Madigan R, Young A, Angeletti M, Wingard RL, Kahn C, Nissenson AR, Maddux FW, Abbott KC, Landis JR.

J Am Soc Nephrol. 2019 May;30(5):890-903. doi: 10.1681/ASN.2018090945. Epub 2019 Apr 18.

PMID:
31000566
3.

High-Dose Seasonal Influenza Vaccine in Patients Undergoing Dialysis.

Miskulin DC, Weiner DE, Tighiouart H, Lacson EK Jr, Meyer KB, Dad T, Manley HJ.

Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1703-1711. doi: 10.2215/CJN.03390318. Epub 2018 Oct 23.

PMID:
30352787
4.

Evaluation of non-response to the In-Center Hemodialysis Consumer Assessment of Healthcare Providers and Systems (ICH CAHPS) survey.

Dad T, Tighiouart H, Fenton JJ, Lacson E Jr, Meyer KB, Miskulin DC, Weiner DE, Richardson MM.

BMC Health Serv Res. 2018 Oct 19;18(1):790. doi: 10.1186/s12913-018-3618-4.

5.

In-Center Hemodialysis: Time for a Paradigm Shift.

Gul A, Miskulin DC, Harford A, Zager P.

J Am Soc Nephrol. 2018 Oct;29(10):2452-2454. doi: 10.1681/ASN.2018030269. Epub 2018 Sep 5. No abstract available.

PMID:
30185467
6.

Association of Intradialytic Hypertension with Left Ventricular Mass in Hypertensive Hemodialysis Patients Enrolled in the Blood Pressure in Dialysis (BID) Study.

Shamir AR, Karembelkar A, Yabes J, Yao Y, Miskulin D, Gassman J, Ploth D, Negrea L, Paine S, Rahman M, Kwong RY, Zager P, Jhamb M.

Kidney Blood Press Res. 2018;43(3):882-892. doi: 10.1159/000490336. Epub 2018 May 30.

7.

Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease.

Dad T, Abebe KZ, Bae KT, Comer D, Torres VE, Czarnecki PG, Schrier RW, Steinman TI, Moore CG, Chapman AB, Kaya D, Tao C, Braun WE, Winklhofer FT, Brosnahan G, Hogan MC, Miskulin DC, Rahbari Oskoui F, Flessner MF, Perrone RD.

Kidney Int Rep. 2018 Jan 6;3(3):619-624. doi: 10.1016/j.ekir.2017.12.011. eCollection 2018 May.

8.

A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease.

Seliger SL, Abebe KZ, Hallows KR, Miskulin DC, Perrone RD, Watnick T, Bae KT.

Am J Nephrol. 2018;47(5):352-360. doi: 10.1159/000488807. Epub 2018 May 18.

9.

Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.

Brosnahan GM, Abebe KZ, Moore CG, Rahbari-Oskoui FF, Bae KT, Grantham JJ, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Miskulin DC, Steinman TI, Torres VE; HALT-PKD Trial Investigators.

Am J Kidney Dis. 2018 May;71(5):666-676. doi: 10.1053/j.ajkd.2017.10.023. Epub 2018 Jan 3.

10.

BP in Dialysis: Results of a Pilot Study.

Miskulin DC, Gassman J, Schrader R, Gul A, Jhamb M, Ploth DW, Negrea L, Kwong RY, Levey AS, Singh AK, Harford A, Paine S, Kendrick C, Rahman M, Zager P.

J Am Soc Nephrol. 2018 Jan;29(1):307-316. doi: 10.1681/ASN.2017020135. Epub 2017 Dec 6.

11.

ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing.

Braun WE, Abebe KZ, Brosnahan G, Patterson CG, Chapman AB, Harris PC, Hogan MC, Perrone RD, Torres VE, Miskulin DC, Steinman TI, Winklhofer FT, Rahbari-Oskoui FF, Czarnecki PG, Bae KT, Grantham JJ, Flessner MF, Schrier RW.

Am J Kidney Dis. 2018 Feb;71(2):294-296. doi: 10.1053/j.ajkd.2017.09.008. Epub 2017 Dec 2. No abstract available.

12.

A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease.

Perrone RD, Mouksassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, Torres VE, Miskulin DC, Broadbent S, Marier JF.

Kidney Int Rep. 2017 Feb 21;2(3):451-460. doi: 10.1016/j.ekir.2017.02.011. eCollection 2017 May.

13.

Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease.

Perrone RD, Mouksassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, Torres VE, Miskulin DC, Broadbent S, Marier JF.

Kidney Int Rep. 2017 Jan 16;2(3):442-450. doi: 10.1016/j.ekir.2017.01.003. eCollection 2017 May. Erratum in: Kidney Int Rep. 2018 May 22;3(4):1015.

14.

Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.

Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M.

J Am Soc Nephrol. 2018 Feb;29(2):571-578. doi: 10.1681/ASN.2017070819. Epub 2017 Nov 8.

15.

Infection Monitoring in Dialysis Units: A Plea for "Cleaner" Data.

Miskulin DC, Gul A.

Clin J Am Soc Nephrol. 2017 Jul 7;12(7):1038-1039. doi: 10.2215/CJN.05220517. Epub 2017 Jun 29. No abstract available.

16.

Blood Pressure Management in Hemodialysis Patients: What We Know And What Questions Remain.

Miskulin DC, Weiner DE.

Semin Dial. 2017 May;30(3):203-212. doi: 10.1111/sdi.12586. Epub 2017 Mar 6. Review.

PMID:
28264150
17.

Antihypertensive medications and risk of death and hospitalizations in US hemodialysis patients: Evidence from a cohort study to inform hypertension treatment practices.

Shafi T, Sozio SM, Luly J, Bandeen-Roche KJ, St Peter WL, Ephraim PL, McDermott A, Herzog CA, Crews DC, Scialla JJ, Tangri N, Miskulin DC, Michels WM, Jaar BG, Zager PG, Meyer KB, Wu AW, Boulware LE; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators.

Medicine (Baltimore). 2017 Feb;96(5):e5924. doi: 10.1097/MD.0000000000005924.

18.

Vascular imaging for hemodialysis vascular access planning.

McGill RL, Ruthazer R, Lacson E Jr, Meyer KB, Miskulin DC, Weiner DE.

Hemodial Int. 2017 Oct;21(4):490-497. doi: 10.1111/hdi.12513. Epub 2016 Nov 20.

19.

Intradialytic hypotension.

Gul A, Miskulin D, Harford A, Zager P.

Curr Opin Nephrol Hypertens. 2016 Nov;25(6):545-550. Review.

PMID:
27606498
20.

Intravenous iron administration strategies and anemia management in hemodialysis patients.

Michels WM, Jaar BG, Ephraim PL, Liu Y, Miskulin DC, Tangri N, Crews DC, Scialla JJ, Shafi T, Sozio SM, Bandeen-Roche K, Cook CJ, Meyer KB, Boulware LE; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators.

Nephrol Dial Transplant. 2017 Jan 1;32(1):173-181. doi: 10.1093/ndt/gfw316.

21.

Peripherally Inserted Central Catheters and Hemodialysis Outcomes.

McGill RL, Ruthazer R, Meyer KB, Miskulin DC, Weiner DE.

Clin J Am Soc Nephrol. 2016 Aug 8;11(8):1434-40. doi: 10.2215/CJN.01980216. Epub 2016 Jun 23.

22.

A β-Blocker Trial in Dialysis Patients: Is It Feasible and Worthwhile?

Miskulin D, Sarnak M.

Am J Kidney Dis. 2016 Jun;67(6):822-5. doi: 10.1053/j.ajkd.2016.03.413. No abstract available.

PMID:
27211366
23.

Comparison of Prescribed and Measured Dialysate Sodium: A Quality Improvement Project.

Gul A, Miskulin DC, Paine SS, Narsipur SS, Arbeit LA, Harford AM, Weiner DE, Schrader R, Horowitz BL, Zager PG.

Am J Kidney Dis. 2016 Mar;67(3):439-45. doi: 10.1053/j.ajkd.2015.11.004. Epub 2016 Jan 6.

PMID:
26776538
24.

Ergocalciferol Supplementation in Hemodialysis Patients With Vitamin D Deficiency: A Randomized Clinical Trial.

Miskulin DC, Majchrzak K, Tighiouart H, Muther RS, Kapoian T, Johnson DS, Weiner DE.

J Am Soc Nephrol. 2016 Jun;27(6):1801-10. doi: 10.1681/ASN.2015040468. Epub 2015 Dec 17.

25.

Closeout of the HALT-PKD trials.

Moore CG, Spillane S, Simon G, Maxwell B, Rahbari-Oskoui FF, Braun WE, Chapman AB, Schrier RW, Torres VE, Perrone RD, Steinman TI, Brosnahan G, Czarnecki PG, Harris PC, Miskulin DC, Flessner MF, Bae KT, Abebe KZ, Hogan MC.

Contemp Clin Trials. 2015 Sep;44:48-55. doi: 10.1016/j.cct.2015.07.017. Epub 2015 Jul 29.

26.

Satisfaction with Care of Patients on Hemodialysis.

Richardson MM, Paine SS, Grobert ME, Stidley CA, Gabbay E, Harford AM, Zager PG, Miskulin DC, Meyer KB.

Clin J Am Soc Nephrol. 2015 Aug 7;10(8):1428-34. doi: 10.2215/CJN.11241114. Epub 2015 Jun 30.

27.

Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).

Perrone RD, Neville J, Chapman AB, Gitomer BY, Miskulin DC, Torres VE, Czerwiec FS, Dennis E, Kisler B, Kopko S, Krasa HB, LeRoy E, Castedo J, Schrier RW, Broadbent S.

Am J Kidney Dis. 2015 Oct;66(4):583-90. doi: 10.1053/j.ajkd.2015.04.044. Epub 2015 Jun 15. Review.

PMID:
26088508
28.

Epidemiology of hypertension in CKD.

Horowitz B, Miskulin D, Zager P.

Adv Chronic Kidney Dis. 2015 Mar;22(2):88-95. doi: 10.1053/j.ackd.2014.09.004. Review.

PMID:
25704344
29.

Blood pressure in early autosomal dominant polycystic kidney disease.

Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB; HALT-PKD Trial Investigators.

N Engl J Med. 2014 Dec 11;371(24):2255-66. doi: 10.1056/NEJMoa1402685. Epub 2014 Nov 15.

30.

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD; HALT-PKD Trial Investigators.

N Engl J Med. 2014 Dec 11;371(24):2267-76. doi: 10.1056/NEJMoa1402686. Epub 2014 Nov 15.

31.

Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study.

Tangri N, Miskulin DC, Zhou J, Bandeen-Roche K, Michels WM, Ephraim PL, McDermott A, Crews DC, Scialla JJ, Sozio SM, Shafi T, Jaar BG, Meyer K, Boulware LE; DEcIDE Network Patient Outcomes in End-Stage Renal Disease Study Investigators.

Nephrol Dial Transplant. 2015 Apr;30(4):667-75. doi: 10.1093/ndt/gfu349. Epub 2014 Nov 2.

32.

Intravenous iron exposure and mortality in patients on hemodialysis.

Miskulin DC, Tangri N, Bandeen-Roche K, Zhou J, McDermott A, Meyer KB, Ephraim PL, Michels WM, Jaar BG, Crews DC, Scialla JJ, Sozio SM, Shafi T, Wu AW, Cook C, Boulware LE; Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Network Patient Outcomes in End Stage Renal Disease Study Investigators.

Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1930-9. doi: 10.2215/CJN.03370414. Epub 2014 Oct 15.

33.

Liver involvement in early autosomal-dominant polycystic kidney disease.

Hogan MC, Abebe K, Torres VE, Chapman AB, Bae KT, Tao C, Sun H, Perrone RD, Steinman TI, Braun W, Winklhofer FT, Miskulin DC, Rahbari-Oskoui F, Brosnahan G, Masoumi A, Karpov IO, Spillane S, Flessner M, Moore CG, Schrier RW.

Clin Gastroenterol Hepatol. 2015 Jan;13(1):155-64.e6. doi: 10.1016/j.cgh.2014.07.051. Epub 2014 Aug 9.

34.

An instrumental variable approach finds no associated harm or benefit with early dialysis initiation in the United States.

Scialla JJ, Liu J, Crews DC, Guo H, Bandeen-Roche K, Ephraim PL, Tangri N, Sozio SM, Shafi T, Miskulin DC, Michels WM, Jaar BG, Wu AW, Powe NR, Boulware LE; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators.

Kidney Int. 2014 Oct;86(4):798-809. doi: 10.1038/ki.2014.110. Epub 2014 Apr 30. Erratum in: Kidney Int. 2016 Apr;89(4):957. Kim, Jeonyong [corrected to Kim, Jeongyong].

35.

Comparative effectiveness of early versus conventional timing of dialysis initiation in advanced CKD.

Crews DC, Scialla JJ, Boulware LE, Navaneethan SD, Nally JV Jr, Liu X, Arrigain S, Schold JD, Ephraim PL, Jolly SE, Sozio SM, Michels WM, Miskulin DC, Tangri N, Shafi T, Wu AW, Bandeen-Roche K; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators.

Am J Kidney Dis. 2014 May;63(5):806-15. doi: 10.1053/j.ajkd.2013.12.010. Epub 2014 Feb 6.

36.

Predialysis systolic BP variability and outcomes in hemodialysis patients.

Shafi T, Sozio SM, Bandeen-Roche KJ, Ephraim PL, Luly JR, St Peter WL, McDermott A, Scialla JJ, Crews DC, Tangri N, Miskulin DC, Michels WM, Jaar BG, Herzog CA, Zager PG, Meyer KB, Wu AW, Boulware LE; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators.

J Am Soc Nephrol. 2014 Apr;25(4):799-809. doi: 10.1681/ASN.2013060667. Epub 2014 Jan 2.

37.

Trends in anemia management in US hemodialysis patients 2004-2010.

Miskulin DC, Zhou J, Tangri N, Bandeen-Roche K, Cook C, Ephraim PL, Crews DC, Scialla JJ, Sozio SM, Shafi T, Jaar BG, Boulware LE; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators.

BMC Nephrol. 2013 Dec 1;14:264. doi: 10.1186/1471-2369-14-264.

38.

Patterns in blood pressure medication use in US incident dialysis patients over the first 6 months.

St Peter WL, Sozio SM, Shafi T, Ephraim PL, Luly J, McDermott A, Bandeen-Roche K, Meyer KB, Crews DC, Scialla JJ, Miskulin DC, Tangri N, Jaar BG, Michels WM, Wu AW, Boulware LE; DEcIDE Network Patient Outcomes in End-Stage Renal Disease Study Investigators.

BMC Nephrol. 2013 Nov 12;14:249. doi: 10.1186/1471-2369-14-249.

39.

Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.

Miskulin DC, Abebe KZ, Chapman AB, Perrone RD, Steinman TI, Torres VE, Bae KT, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Moore CG, Flessner MF, Schrier RW; HALT-PKD Study.

Am J Kidney Dis. 2014 Feb;63(2):214-26. doi: 10.1053/j.ajkd.2013.08.017. Epub 2013 Nov 1.

40.

Predialysis health, dialysis timing, and outcomes among older United States adults.

Crews DC, Scialla JJ, Liu J, Guo H, Bandeen-Roche K, Ephraim PL, Jaar BG, Sozio SM, Miskulin DC, Tangri N, Shafi T, Meyer KB, Wu AW, Powe NR, Boulware LE; Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Patient Outcomes in End Stage Renal Disease Study Investigators.

J Am Soc Nephrol. 2014 Feb;25(2):370-9. doi: 10.1681/ASN.2013050567. Epub 2013 Oct 24.

41.

Design of the Blood Pressure Goals in Dialysis pilot study.

Gul A, Miskulin D, Gassman J, Harford A, Horowitz B, Chen J, Paine S, Bedrick E, Kusek JW, Unruh M, Zager P; BID Pilot Study Investigators.

Am J Med Sci. 2014 Feb;347(2):125-30. doi: 10.1097/MAJ.0b013e31827daee5.

42.

Comparative effectiveness studies to improve clinical outcomes in end stage renal disease: the DEcIDE patient outcomes in end stage renal disease study.

Boulware LE, Tangri N, Ephraim PL, Scialla JJ, Sozio SM, Crews DC, Shafi T, Miskulin DC, Liu J, St Peter W, Jaar BG, Wu AW, Powe NR, Navaneethan SD, Bandeen-Roche K; DEcIDE ESRD Patient Outcomes in Renal Disease Study Investigators.

BMC Nephrol. 2012 Dec 6;13:167. doi: 10.1186/1471-2369-13-167.

43.

Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review.

Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K.

Ann Intern Med. 2012 Jun 5;156(11):785-95, W-270, W-271, W-272, W-273, W-274, W-275, W-276, W-277, W-278. doi: 10.7326/0003-4819-156-6-201203200-00391. Epub 2012 Feb 6. Review.

PMID:
22312131
44.

Analysis of baseline parameters in the HALT polycystic kidney disease trials.

Torres VE, Chapman AB, Perrone RD, Bae KT, Abebe KZ, Bost JE, Miskulin DC, Steinman TI, Braun WE, Winklhofer FT, Hogan MC, Oskoui FR, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin DR, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Meyers CM, Schrier RW; HALT PKD Study Group.

Kidney Int. 2012 Mar;81(6):577-85. doi: 10.1038/ki.2011.411. Epub 2011 Dec 28.

45.

Both patient and facility contribute to achieving the Centers for Medicare and Medicaid Services' pay-for-performance target for dialysis adequacy.

Tangri N, Tighiouart H, Meyer KB, Miskulin DC.

J Am Soc Nephrol. 2011 Dec;22(12):2296-302. doi: 10.1681/ASN.2010111137. Epub 2011 Oct 24.

46.

Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease.

Perrone RD, Abebe KZ, Schrier RW, Chapman AB, Torres VE, Bost J, Kaya D, Miskulin DC, Steinman TI, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin D, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Bae KT; HALT PKD Study Group, Meyers CM.

Clin J Am Soc Nephrol. 2011 Oct;6(10):2508-15. doi: 10.2215/CJN.04610511. Epub 2011 Sep 8.

47.

Short-term reproducibility of ambulatory blood pressure monitoring in autosomal dominant polycystic kidney disease.

Rahbari-Oskoui FF, Miskulin DC, Hogan MC, Fielder O, Torres VE, Bost JE, Chapman AB.

Blood Press Monit. 2011 Apr;16(2):47-54. doi: 10.1097/MBP.0b013e328344c6f3.

48.

Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease.

Heffernan KS, Kuvin JT, Sarnak MJ, Perrone RD, Miskulin DC, Rudym D, Chandra P, Karas RH, Menon V.

Nephrol Dial Transplant. 2011 Aug;26(8):2515-21. doi: 10.1093/ndt/gfq806. Epub 2011 Feb 3.

49.

A validation study of the Canadian Organ Replacement Register.

Moist LM, Richards HA, Miskulin D, Lok CE, Yeates K, Garg AX, Trpeski L, Chapman A, Amuah J, Hemmelgarn BR.

Clin J Am Soc Nephrol. 2011 Apr;6(4):813-8. doi: 10.2215/CJN.06680810. Epub 2011 Jan 21.

50.

Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry.

Tangri N, Wagner M, Griffith JL, Miskulin DC, Hodsman A, Ansell D, Naimark DM.

Am J Kidney Dis. 2011 Mar;57(3):415-21. doi: 10.1053/j.ajkd.2010.08.037. Epub 2010 Dec 4.

PMID:
21131115

Supplemental Content

Loading ...
Support Center